OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
2.200
-0.020 (-0.90%)
At close: Sep 17, 2025, 4:00 PM EDT
2.200
0.00 (0.00%)
After-hours: Sep 17, 2025, 4:00 PM EDT
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OS Therapies Incorporated
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Paul Romness |
Contact Details
Address: 115 Pullman Crossing Road, Suite 103 Grasonville, Maryland 21638 United States | |
| Phone | 410-297-7793 |
| Website | ostherapies.com |
Stock Details
| Ticker Symbol | OSTX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001795091 |
| ISIN Number | US68764Y2072 |
| Employer ID | 82-5118368 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul A. Romness M.P.H. | Founder, Chairman, President and Chief Executive Officer |
| Christopher P. Acevedo | Chief Financial Officer |
| Dr. Robert G. Petit II, Ph.D. | Chief Medical Officer and Chief Scientific Officer |
| Jack Doll | Chief of Staff |
| Gerald E. Commissiong | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2025 | D | Notice of Exempt Offering of Securities |
| Sep 2, 2025 | 8-K | Current Report |
| Aug 26, 2025 | 8-K | Current Report |
| Aug 26, 2025 | ARS | Filing |
| Aug 25, 2025 | EFFECT | Notice of Effectiveness |
| Aug 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 25, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 25, 2025 | 424B5 | Filing |
| Aug 25, 2025 | 424B3 | Prospectus |
| Aug 19, 2025 | 8-K | Current Report |